(Read only)

Complete the index case eligibility criteria in Table 2. Index cases are the primary group being studied. If data, whole slide images (WSIs), pathology reports, and/or tissue are being requested for a comparison group, complete fields in the Comparison Group column of Table 2. For example, in a study comparing cancer cases among Black individuals with cancer cases among White people, the Black cases are the index cases, and the White cases are the comparison group cases. If you are requesting comparison group cases, these criteria and counts should be added to far right column of Table 2. For each additional cancer site being studied (e.g., nasopharynx, oropharynx, etc.), you will be asked to complete a separate Table 2.

Table 2: Case Selection eligibility

* For tissue requests over 200 total cancer cases, the request may need to be fulfilled over multiple calendar years.

Eligibility Criteria	Index Cases	Comparison Cases
Sex	Male Count Female Count Unknown Sex Count All Count	Male Count Female Count Unknown Sex Count All Count
Minimum Age (years)
Maximum Age (years)
Stage at Diagnosis (select all that apply)	In Situ Localized Regional Distant Benign borderline Unknown	In Situ Localized Regional Distant Benign borderline Unknown
Maximum Survival Time (months)
Minimum Survival Time (months)
Earliest Year of Diagnosis (YYYY)	Cases diagnosed between 1 year ago and 9 years ago.	Cases diagnosed between 1 year ago and 9 years ago.
Most Recent Year of Diagnosis (YYYY)	Cases diagnosed between 1 year ago and 9 years ago.	Cases diagnosed between 1 year ago and 9 years ago.
Only Include First Primary Cancer	Yes No Not Sure	Yes No Not Sure
Allow Synchronous Multiple Primaries	Yes No Not Sure	Yes No Not Sure
Allow Metachronous Multiple Primaries	Yes No Not Sure	Yes No Not Sure
Allow Neoadjuvant Treatment	Yes No Not Sure	Yes No Not Sure
Types of Neoadjuvant Treatment Allowed (check all that apply)	Chemotherapy Immunotherapy Hormone therapy Radiation therapy Not sure Other (specify)	Chemotherapy Immunotherapy Hormone therapy Radiation therapy Not sure Other (specify)
Procedure Types Allowed (check all that apply)	Biopsy Surgery Autopsy Not Sure	Biopsy Surgery Autopsy Not Sure
Allow Cases With Only Biopsy Tissue	Yes No Not Sure	Yes No Not Sure
ICD-O-3.2 Morphology Code(s) Excluded*	None Exclude all except:	None Exclude all except:
Biomarker Restrictions	(ex: triple negative breast cancers) For a list of biomarkers captured by SEER, refer to https://apps.naaccr.org/ssdi/list/)	(ex: triple negative breast cancers) For a list of biomarkers captured by SEER, refer to https://apps.naaccr.org/ssdi/list/)

Table 2(a): Breast

* For tissue requests over 200 total cancer cases, the request may need to be fulfilled over multiple calendar years.

Eligibility Criteria	Index Cases	Comparison Cases
Sex	Male Count Female Count Unknown Sex Count All Count	Male Count Female Count Unknown Sex Count All Count
Minimum Age (years)
Maximum Age (years)
Stage at Diagnosis (select all that apply)	In Situ Localized Regional Distant Benign borderline Unknown	In Situ Localized Regional Distant Benign borderline Unknown
Maximum Survival Time (months)
Minimum Survival Time (months)
Earliest Year of Diagnosis (YYYY)	Cases diagnosed between 1 year ago and 9 years ago.	Cases diagnosed between 1 year ago and 9 years ago.
Most Recent Year of Diagnosis (YYYY)	Cases diagnosed between 1 year ago and 9 years ago.	Cases diagnosed between 1 year ago and 9 years ago.
Only Include First Primary Cancer	Yes No Not Sure	Yes No Not Sure
Allow Synchronous Multiple Primaries	Yes No Not Sure	Yes No Not Sure
Allow Metachronous Multiple Primaries	Yes No Not Sure	Yes No Not Sure
Allow Neoadjuvant Treatment	Yes No Not Sure	Yes No Not Sure
Types of Neoadjuvant Treatment Allowed (check all that apply)	Chemotherapy Immunotherapy Hormone therapy Radiation therapy Not sure Other (specify)	Chemotherapy Immunotherapy Hormone therapy Radiation therapy Not sure Other (specify)
Procedure Types Allowed (check all that apply)	Biopsy Surgery Autopsy Not Sure	Biopsy Surgery Autopsy Not Sure
Allow Cases With Only Biopsy Tissue	Yes No Not Sure	Yes No Not Sure
ICD-O-3.2 Morphology Code(s) Excluded*	None Exclude all except:	None Exclude all except:
Biomarker Restrictions	(ex: triple negative breast cancers) For a list of biomarkers captured by SEER, refer to https://apps.naaccr.org/ssdi/list/)	(ex: triple negative breast cancers) For a list of biomarkers captured by SEER, refer to https://apps.naaccr.org/ssdi/list/)

No tissue selected

Table 1: Study Tissue Selection and Processing Requirements

Requirement	Primary Tumor	Non-Tumor (complete column if applicable)	Metastatis (complete column if applicable)
Tissue Requirements
Requirement	Required If available Not required	Required If available Not required	Required If available Not required
Preferred Specimen Site Term(s) (ex: lymph node, breast, etc.)
Total Amount of Tissue Needed (microns)
Number of Blocks Needed
Specimen Selection
Minimum Tumor Cellularity (%)
Maximum Tumor Necrosis (%)
Specimen Processing Tissue processing requested
Unstained Slides (if checked, answer below)
Unstained slides number (total)
Unstained slides thickness (microns)
H&E-Stained Slides (if checked, answer below)
H&E-stained slides number (total)
H&E-stained slides thickness (microns)
H&E-stained slides level ratio (number of unstained slides to each H&E-stained slide)
Scrolls in Tube(s) (if checked, answer below)
Scrolls number (total)
Scrolls thickness (microns)
Ribbons (if checked, answer below)
Number of sections (total)
Ribbons thickness (microns)
Whole Slide Imaging (.svs images generated via Leica/Aperio scanners)
Scanning Magnification	20x 40x Unknown	20x 40x Unknown	20x 40x Unknown
Maximum Number of H&E-Stained Slides per Case to Scan
Pathologist Prescreening and Selection	Yes No Not Sure	Yes No Not Sure	Yes No Not Sure

A funding support letter is required to show proof of grant or other funding. If the project is funded by NIH, then a data sharing plan is required. For further details, refer to NIH Data Management and Sharing Policy.

A funding support letter is required to show proof of grant or other funding. If the project is funded by NIH, then a data sharing plan is required. For further details, refer to NIH Data Management and Sharing Policy.